GALLIUM — A Study of Obinutuzumab Plus Chemotherapy Compared With Rituximab Plus Chemotherapy in Participants With Previously Untreated Follicular Lymphoma

Phase 3 · 2017 · Follicular Lymphoma

Design

Open-label randomized trial of obinutuzumab-chemotherapy versus rituximab-chemotherapy induction followed by anti-CD20 maintenance.

Population

Previously untreated advanced follicular lymphoma (and other indolent NHL) requiring therapy.

Primary Endpoint

investigator-assessed progression-free survival (PFS)

Key Result

3-year PFS 80.0% vs 73.3% (HR 0.66, p=0.001) favoring obinutuzumab, with more grade 3-5 adverse events and no OS difference.

Guideline Impact

NCCN-recommended frontline immunochemotherapy option for follicular lymphoma